Physician

Andrei Mihnea Dobrescu, M.D.

According to 2025 Medicare claims, Andrei Dobrescu, M.D. (NPI: 1093949224) practices hematology/oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Somerset, NJ. This provider's primary affiliated billing organization is TITAN HEALTH PARTNERS LLC (NPI: 1790396281; TIN: 852303328) and primary practice location at 08807-2943. Dobrescu is affiliated with the Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Dobrescu's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 550 traditional Medicare patients, billed 160,288 HCPCS/CPT codes, and received $2,980,225 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,171 prescription claims across 159 beneficiaries totaling $5,412,990 in drug costs, led by Revlimid (Lenalidomide). DME data shows 40 claims. Open Payments data shows 14 records totaling $270. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,717,307 to $2,980,225. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,044,322 to $5,412,990. In contrast, DME billing represents a smaller volume and declined steadily, from $5,773 to $2,861.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	413	123,713	$1,717,307
2016	579	94,321	$1,699,444
2017	644	124,781	$1,971,722
2018	629	109,361	$2,385,781
2019	596	101,561	$1,654,038
2020	622	92,851	$1,725,159
2021	601	119,660	$2,178,190
2022	517	105,083	$1,865,108
2023	565	133,087	$2,710,976
2024	550	160,288	$2,980,225

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	93	526	$1,044,322
2016	121	649	$1,012,621
2017	120	708	$1,327,037
2018	109	701	$1,616,157
2019	126	667	$1,703,680
2020	124	745	$2,757,267
2021	133	856	$3,305,935
2022	151	868	$3,434,686
2023	163	1,078	$4,416,023
2024	159	1,171	$5,412,990

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	65	$5,773
2016	N/R	132	$22,258
2017	N/R	154	$7,059
2018	N/R	71	$2,937
2019	N/R	135	$11,271
2020	N/R	30	$3,297
2021	N/R	13	$1,986
2022	N/R	35	$1,609
2023	N/R	26	$5,264
2024	N/R	40	$963

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	339	994	$112
96372	Injection of drug or substance under skin or into muscle	124	701	$13
36415	Insertion of needle into vein for collection of blood sample	296	950	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	230	705	$8
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	148	422	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	71	1,862	$1,074,827
Brukinsa	Zanubrutinib	30	900	$445,687
Imbruvica	Ibrutinib	25	700	$371,443
Neulasta	Pegfilgrastim	44	994	$338,547
Jakafi	Ruxolitinib Phosphate	18	540	$314,154

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	13	$473
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	13	$249
J9190	Injection, fluorouracil, 500 mg	N	N/R	14	$241

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$270	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrei Mihnea Dobrescu, M.D.?

Tedicare shows public-source Medicare data for Andrei Mihnea Dobrescu, M.D. (NPI 1093949224), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrei Mihnea Dobrescu, M.D. have ACO affiliation data?

Andrei Mihnea Dobrescu, M.D. is shown with ACO affiliation data for Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Andrei Mihnea Dobrescu, M.D.?

Andrei Mihnea Dobrescu, M.D. is linked to TITAN HEALTH PARTNERS LLC (billing NPI 1790396281) in the available physician profile data.

Does Andrei Mihnea Dobrescu, M.D. have Open Payments data?

Andrei Mihnea Dobrescu, M.D. has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.